NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months.
Related Questions
How will the acquisition and upfront $885 million payment affect Royalty Pharma’s cash balance and valuation in the short term?
What are the projected royalty streams from Imdelltra and how do they compare to Royalty Pharma’s existing portfolio and peers in the royalty‑fund sector?
What are the regulatory and commercial milestones for Imdelltra, and how could delays or approvals impact the expected return on this deal?